S
S. Li
Researcher at Genentech
Publications - 12
Citations - 2572
S. Li is an academic researcher from Genentech. The author has contributed to research in topics: Sunitinib & Atezolizumab. The author has an hindex of 7, co-authored 12 publications receiving 1859 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini,Thomas Powles,Michael B. Atkins,Bernard Escudier,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Jae-Lyun Lee,Robert E. Hawkins,Alain Ravaud,Boris Alekseev,Michael Staehler,Motohide Uemura,Ugo De Giorgi,Begoña Mellado,Camillo Porta,Bohuslav Melichar,Howard Gurney,Jens Bedke,Toni K. Choueiri,Francis Parnis,Tarik Khaznadar,Alpa Thobhani,S. Li,Elisabeth Piault-Louis,Gretchen Frantz,Mahrukh Huseni,Christina Schiff,Marjorie C. Green,Robert J. Motzer +31 more
TL;DR: Results of IMmotion151 support atezolizumab plus bevacIZumab as a first-line treatment option for selected patients with advanced renal cell carcinoma and showed a favourable safety profile.
Journal ArticleDOI
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
Robert J. Motzer,Thomas Powles,Michael B. Atkins,Bernard Escudier,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Jae-Lyun Lee,Robert E. Hawkins,Alain Ravaud,Boris Alekseev,Michael Staehler,Motohide Uemura,Francis Donaldson,S. Li,Mahrukh Huseni,Christina Schiff,Brian I. Rini +19 more
TL;DR: The first randomized Phase III trial of a PD-L1/PD-1 pathway inhibitor combined with an anti-VEGF agent in 1L mRCC is described.
Journal ArticleDOI
Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
Brian I. Rini,Mahrukh Huseni,Michael B. Atkins,David F. McDermott,Thomas Powles,Bernard Escudier,Romain Banchereau,Li-Fen Liu,Ning Leng,J. Fan,Jennifer Doss,S. Nalle,Susheela Carroll,S. Li,Christina Schiff,Marjorie C. Green,Robert J. Motzer +16 more